Symbiosis Completes 1,000th Batch of Injectable Drug Product

Symbiosis Pharmaceutical Services, a global CMO, has successfully completed its 1,000th sterile drug product batch. The company supports clients through phase I, II and III clinical trials and commercial-scale manufacturing.

Since the company was founded in 2011, Symbiosis has grown from a Scottish startup into an internationally recognized sterile manufacturer of injectable drug products, supporting both clinical development and commercial supply across a wide range of therapeutic areas.

The company has since delivered complex injectable products spanning monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), viral vectors, small molecules, and advanced therapy medicinal products (ATMPs).

Symbiosis also supported the clinical development of the Oxford University/AstraZeneca COVID-19 vaccine, manufacturing nearly one million doses at its Stirling facility to support clinical trials.

“Reaching our 1,000th batch is a proud moment for everyone at Symbiosis,” said Colin MacKay, CEO of Symbiosis. “As global demand for sterile drug products rises, it reflects our commitment to manufacturing excellence and our shared purpose of helping deliver life-saving medicines to patients faster.”